Drug Trial Radar · NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,594
Planned (sponsor's estimate)
Start
Sep 8, 2022
Primary completion
Apr 2028
Study completion Apr 2032
Sponsor
- Lead sponsor
- European Myeloma Network B.V.Research network
- Sponsor type
- Research network
- Collaborators
- Janssen Pharmaceutica
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Conditions
- Multiple Myeloma
Interventions
TeclistamabDrug
Teclistamab will be administered via a subcutaneous injection (SC)
LenalidomideDrug
Lenalidomide will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: from randomization to the date of disease progression or death (approximately up to 8 years)
- Minimal Residual Disease (MRD)-negative Complete Response (CR)Time frame: at month 12
Locations
201 sites in 25 countries. Site status is shown where the registry gives one.
Banner University Medical Center Tucson, University of Arizona
Phoenix, Arizona
UCLA Medical Center
Los Angeles, California
University of California-Davis Cancer Center
Sacramento, California
University of California, San Diego (UCSD) Medical Center
San Diego, California
University of Colorado Hospital
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Yale New Haven Hospital
New Haven, Connecticut
Christiana Care
Newark, Delaware
Sibley Memorial Hospital
Washington D.C., District of Columbia
AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group
Orlando, Florida
Moffitt at Memorial Healthcare System
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
University of Chicago
Chicago, Illinois
University of Illinois Medical Center at Chicago
Chicago, Illinois
Greenebaum Cancer Center UM of MD
Baltimore, Maryland
John Hopkins
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mount Sinai Medical Center - 2
New York, New York
Montefiore Medical Cente
The Bronx, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University
Durham, North Carolina
East Carolina University
Greenville, North Carolina
University of Cincinnati
Cincinnati, Ohio
Seidman Cancer Center-University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio State Medical Center, James Cancer Center
Columbus, Ohio
Ohio Health Research Institute
Columbus, Ohio
Lehigh Valley Health Network
Allentown, Pennsylvania
Penn Medicine Lancaster General
Lancaster, Pennsylvania
Abramson Cancer Center University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Gibbs Cancer Center
Spartanburg, South Carolina
Vanderbilt-Ingram Cancer Center (VICC)
Nashville, Tennessee
Houston Methodist Hospital
Houston, Texas
Virginia Oncology Associates
Norfolk, Virginia
St Vincent HSHS (Green Bay Oncology)
Green Bay, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
Hospital Italiano
Buenos Aires, Argentina
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.